Study: Anemia meds double clot risk

A decade-long study of 55,000 cancer patients adds to mounting evidence that anemia drugs such as Amgen's Epogen and Johnson & Johnson's Procrit boost the risk of blood clots significantly. Report

Suggested Articles

WuXi AppTec has appointed Celgene CAR-T program veteran David Chang to lead its cell and gene therapy CDMO, WuXi Advanced Therapies.

Maryland-based Emergent BioSolutions has won a $628 million contract with BARDA to manufacture targeted COVID-19 vaccine hopefuls.

About 76% remdesivir patients had at least one point of clinical improvement on a 7-point scale at day 11, versus 66% of patients on standard care.